

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): January 12, 2021

Endo International plc
(Exact Name of Registrant as Specified in Its Charter)

Ireland
(State or other jurisdiction
of incorporation)

001-36326
(Commission File Number)

68-0683755
(IRS Employer
Identification No.)

**First Floor, Minerva House, Simmonscourt Road
Ballsbridge, Dublin 4, Ireland**
(Address of principal executive offices)

Not Applicable
(Zip Code)

Registrant's telephone number, including area code 011-353-1-268-2000

Not Applicable
Former name or former address, if changed since last report

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Ordinary shares, nominal value \$0.0001 per share

Trading symbol(s)
ENDP

Name of each exchange on which registered
The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01. Regulation FD Disclosure.

On January 12, 2021, Endo International plc (the "Company") intends to make a presentation at the J.P. Morgan Healthcare Conference (the "Presentation"), a copy of which is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The Presentation will also be available on the Company's website at www.endo.com.

The information in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information contained in this Item 7.01 and in Exhibit 99.1 attached hereto shall not be incorporated into any registration statement or other document filed by the Company with the U.S. Securities and Exchange Commission under the Securities Act of 1933, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

<u>Number</u>	<u>Description</u>
99.1	Investor Presentation of Endo International plc dated as of January 12, 2021
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

ENDO INTERNATIONAL PLC

By: /s/ Matthew J. Maletta
Name: Matthew J. Maletta
Title: Executive Vice President,
Chief Legal Officer and Company Secretary

Dated: January 12, 2021



Forward Looking Statements

This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Canadian securities legislation. Statements including words such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “plan,” “will,” “may,” “look forward,” “intend,” “guidance,” “future projects” or similar expressions are forward looking statements. Because these statements reflect our current views, expectations and concerning future events, these forward looking statements involve risks and uncertainties. Although Endo believes that these forward looking statements information are based upon reasonable assumptions and expectations, readers should not place undue reliance on them, or any other forward looking statements or information in this news release. Investors should note that many factors, as more fully described in the documents filed by Endo with securities regulators in the United States and Canada including under the caption “Risk Factors” in Endo’s Form 10-K, Form 10-Q and Form 8-K filings, as applicable to the Securities and Exchange Commission and with securities regulators in Canada on System for Electronic Document Analysis and Retrieval (“SEDAR”) otherwise enumerated herein or therein, could affect Endo’s future financial results and could cause Endo’s actual results to differ materially from those expressed in any forward looking statements. The forward looking statements in this presentation are qualified by these risk factors. Endo assumes no obligation to publicly update any forward looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities law.



Endo: A Specialty Pharmaceutical Company

Branded
Pharmaceuticals



Sterile
Injectables



Generic
Pharmaceuticals



Q3' YTD 2020 segment revenue



International Pharmaceuticals revenue Q3' YTD 2020 revenues of \$76mn



OUR VISION

Helping everyone we serve live their best life

OUR MISSION

We develop and deliver life-enhancing products through focused execution.



Our Strategic Priorities

Expand & Enhance Our Portfolio

We are investing to build a more differentiated and durable portfolio that benefits our customers and creates sustainable long-term value.

Reinvent How We Work

We are embracing the future by accelerating new ways of working to better serve our customers, promote innovation, and improve productivity.

Be A Force For Good

We are committed to the adoption of more sustainable practices that positively impact our stakeholders, including the promotion of diversity & inclusion in all we do.



Our Progress

Expand & Enhance Our Portfolio

- XIAFLEX[®] maximization
- Qwo[®] approval & launch prep
- BioSpecifics acquisition
- Sterile Injectables evolution

Reinvent How We Work

- COVID-19 response
- Optimize Gx operations
- Simplified organization
- Focused outsourcing

Be A Force For Good

- ESG key advancements
- Commitment to DE&I
- Novavax COVID vaccine



XIAFLEX®: Investing to Maximize Long Term Value

Current On-market Indications

EMPOWER patients to seek nonsurgical treatment

ENHANCE new injector training and engagement

ADVANCE existing injector utilization



Dupuytren's Contracture

Peyronie's Disease

Patients Diagnosed

Patients Treated

Treat XIAF



Current Development Programs*

Adhesive Capsulitis

~230K

Surgeries annually

2-5%

Prevalence rate**

First patient enrolled in Phase IIB study **Jul 2020**

Plantar Fibromatosis

~430K

Surgeries annually

5-11%

Prevalence rate**

Interim Analysis from Phase I study expected **Q1 2021**


Source: 2019 IQVIA data, Market Research
*Multiple additional indications under review
** US Adult Population



QWO®: 1st FDA Approved Injectable for Cellulite



~8.5 million U.S. women
are potential candidates



1. Source: US Census 2021 Projected Population

2. Source: Endo Cellulite Consumer Segmentation Research 2018

3. Survey Question #7. Includes respondents that answered "I have some discretionary income, but I really have to prioritize how I use it" or "I have enough discretionary income to spend as I like without making hard trade-offs"

4. Survey Question #13. Includes respondents that answered "Somewhat Bothered", "Very Bothered", and "Extremely Bothered"

5. Survey Question #9 - How open are you to getting an aesthetic treatment. Includes respondents that answered "Very Open", "Extremely Open" or "Somewhat Open" and has spent \$1 or more on aesthetic treatments in the past 12 months (Survey Question #D2)



Integrated Plan to Drive Adoption and Positive Consumer Outcomes

HCP Engagement



HCP Injector Training Program



"Virtual" and in-person HCP Training Programs



HCP Support

1H21

2H21

Consumer Engagement



Unbranded consumer Condition Awareness



Brand Launch Campaign



Integrated DTC Campaign Launch

Ongoing Media, Public and Professional Relations




Endo Completes Acquisition of BioSpecifics



- Transaction closed in late 4Q 2020
- Immediately enhances adjusted EBITDA through the elimination of third party royalty
- Multiple potential additional indications for Xiaflex® and Qwo®, respectively, under review



Sterile Injectables: Moving to a More Differentiated Portfolio



- Reinvesting savings to accelerate ongoing portfolio evolution
- Highly compliant Injectable facility in Rochester, MI supplemented by future capabilities in Indore, I
- Ready-To-Use (RTU) products provide benefits that meet the evolving needs of our customers



Transforming Our Business

- Optimizing generics operations by exiting 4 sites in U.S. and India
- Improving flexibility and reducing certain costs through global business process service providers
- Fully integrating commercial, R&D, & operations functions, increasing effectiveness and driving efficiencies
- Reinvesting expected annual savings of ~\$85-95M to expand and enhance our portfolio

Financial Impact of Planned Strategic Actions

(US \$ in millions)

Cumulative Cash Savings ^[a]	2020	2021	2022
Cost of sales	\$ -	\$ -	\$ 27-30
Operating expenses	-	10-15	18-20
Total	\$ -	\$ 10-15	\$ 45-50

One-time Charges ^[a]	2020 ^[b]	2021	2022
Cash restructuring charges	\$ 55-60	\$ 40-45	\$ 5
Asset impairments	7	-	-
Accelerated depreciation	21	25-30	10-15
Total	\$ 83-88	\$ 65-75	\$ 15-20

[a] Represents full year estimates

[b] Approximately \$67 million of one-time charges was recorded in the third quarter of 2020 which included approximately \$54 million cash and non-cash restructuring charges, respectively.



Our Focus in 2021

Expand &
Enhance
Our Portfolio

Reinvent How
We Work

Be A Force
For Good

- Investing to enhance our portfolio and capabilities
 - Focused on Specialty Branded, Medical Aesthetics and Sterile Injectables
- Strategic actions improving efficiency and effectiveness
 - Expect annualized pre-tax cash savings of \$85–\$95mn by '23
- Maintain financial flexibility and disciplined capital allocation
- Continue sustainability focus





Thank you

